Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trialDerek Alderson, Ruth E. Langley, Heike I. Grabsch et al.|The Lancet Oncology|2017Cited by 223
Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: Results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072).Derek Alderson, David Cunningham, Ruth E. Langley et al.|Journal of Clinical Oncology|2015Cited by 80
COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.Hugo Ford, Janet Dunn, Andrea Marshall et al.|Journal of Clinical Oncology|2013Cited by 32